PMS-ESOMEPRAZOLE DR CAPSULE (DELAYED RELEASE)

البلد: كندا

اللغة: الإنجليزية

المصدر: Health Canada

العنصر النشط:

ESOMEPRAZOLE (ESOMEPRAZOLE MAGNESIUM DIHYDRATE)

متاح من:

PHARMASCIENCE INC

ATC رمز:

A02BC05

INN (الاسم الدولي):

ESOMEPRAZOLE

جرعة:

40MG

الشكل الصيدلاني:

CAPSULE (DELAYED RELEASE)

تركيب:

ESOMEPRAZOLE (ESOMEPRAZOLE MAGNESIUM DIHYDRATE) 40MG

طريقة التعاطي:

ORAL

الوحدات في الحزمة:

30/100

نوع الوصفة الطبية :

Prescription

المجال العلاجي:

PROTON-PUMP INHIBITORS

ملخص المنتج:

Active ingredient group (AIG) number: 0145162002; AHFS:

الوضع إذن:

APPROVED

تاريخ الترخيص:

2014-05-26

خصائص المنتج

_pms-ESOMEPRAZOLE DR Product Monograph _
_Page 1 of 55_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
PMS-ESOMEPRAZOLE DR
Esomeprazole Magnesium Delayed Release Capsules
Delayed-Release Capsules, 20 mg, 40 mg esomeprazole (as esomeprazole
magnesium
dihydrate), Oral
H
+
, K
+
-ATPase Inhibitor
PHARMASCIENCE INC.
6111 Royalmount Ave., Suite 100
Montréal, Canada
H4P 2T4
www.pharmascience.com
Submission Control Number: 258544
Date of Initial Authorization:
MAY 26, 2014
Date of Revision:
MAR 16, 2022
_pms-ESOMEPRAZOLE DR Product Monograph _
_Page 2 of 55_
RECENT MAJOR LABEL CHANGES
7 WARNINGS AND PRECAUTIONS, General
03/2022
7 WARNINGS AND PRECAUTIONS, Gastrointestinal
03/2022
7 WARNINGS AND PRECAUTIONS, 7.1.1 Pregnant Women
03/2022
TABLE OF CONTENTS
Sections or subsections that are not applicable at the time of
authorization are not listed.
RECENT MAJOR LABEL
CHANGES.............................................................................................
2
TABLE OF CONTENTS
...............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................................
4
1
INDICATIONS
.....................................................................................................................
4
1.1
Pediatrics
...............................................................................................................
4
2
CONTRAINDICATIONS........................................................................................................
4
4
DOSAGE AND ADMINISTRATION
.......................................................................................
5
4.1
Dosing Considerations
............................................................................................
5
4.2
Recommended Dose and Dosage
Adjustment.......................................................... 5
4.4
Administration..................................................................